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Abstract: The landmark study of Fletcher and Peto on the natural history of tobacco 
smoke-related chronic airflow obstruction suggested that decline in the forced expiratory 
volume in the first second (FEV1) in chronic obstructive pulmonary disease (COPD) is slow 
at the beginning, becoming faster with more advanced disease. The present authors reviewed 
spirometric data of COPD patients included in the placebo arms of recent clinical trials to assess 
the lung function decline of each stage, defined according to the severity of airflow obstruction 
as proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. 
In large COPD populations the mean rate of FEV1 decline in GOLD stages II and III is between 
47 and 79 mL/year and 56 and 59 mL/year, respectively, and lower than 35 mL/year in GOLD 
stage IV . Few data on FEV1 decline are available for GOLD stage I. Hence, the loss of lung 
function, assessed as expiratory airflow reduction, seems more accelerated and therefore more 
relevant in the initial phases of COPD. To have an impact on the natural history of COPD, it is 
logical to look at the effects of treatment in the earlier stages.
Keywords: chronic obstructive pulmonary disease, decline, forced expiratory volume in 
1 second, FEV1
Introduction
Assumptions about lung function decline occurring in chronic obstructive pulmonary 
disease (COPD) have been greatly influenced by the landmark study of Fletcher and 
Peto1 on the natural history of tobacco smoke–related chronic airflow obstruction.2 
More than 30 years ago, Fletcher and Peto1 measured the forced expiratory volume 
in 1 second (FEV1) every 6 months for an 8-year follow-up period in a cohort of 792 
working men, drawing the well-known graph of FEV1 decline over time in COPD 
(Figure 1). FEV1 was originally expressed as a percentage of the value calculated by 
extrapolation back to the age of 25 years, made equal to 100, and time in years from 
age 25 to age 75.
A lot of information arose from Fletcher and Peto’s1 pioneering work: the individual 
susceptibility to smoking-related lung functional damage, the unavoidable progression 
of the airflow obstruction once COPD is established, the large variability of the abnormal 
lung function decline among different subjects, the possible reduction of the excessive 
FEV1 decline after smoking cessation at all times, and the paucity of self-reported 
symptoms when the airflow reduction is mild to moderate. However, among the various 
messages offered by their analysis, the most retained was that the rate of FEV1 decline 
increased progressively with time in susceptible smokers. In other words, in the COPD 
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patients who smoked, the lower the FEV1, the greater its 
subsequent decline for similar intervals of time.
Some limitations must be acknowledged in the work of 
Fletcher and Peto.1 All subjects were male, their recruitment 
age was between 30 and 59 years only, and the follow-up 
period was relatively short compared with the large time 
range shown on the x-axis of Fletcher and Peto’s1 graph 
(Figure 1). Therefore, the curves shown in the graph were 
largely extrapolated backward and forward with inherent 
inaccuracies, possibly leading to an erroneous picture of the 
phenomenon. Because of this, the present authors believe 
that a false idea of lung function decline in COPD has been 
inculcated in pulmonologists, suggesting that the disease pro-
gresses slowly at the beginning and that the loss of function 
markedly increases only when a given degree of severity has 
been reached. As a consequence, major therapeutic efforts 
have been focused on severe to very severe airflow obstruction 
in COPD patients. Recently, large amounts of data have been 
collected to challenge Fletcher and Peto’s1 hypothesis.
In the framework of the classification of airflow obstruc-
tion severity proposed by Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines,3 the authors 
analyzed the spirometric data of COPD patients enrolled 
in recent prospective clinical trials and randomized in the 
placebo arms to assess the natural rate of FEV1 decline of 
each stage.
Methods
The authors searched the PubMed database and collected 
the data available after 1990 on the average rate of FEV1 
decline found in large observational studies and in recently 
published prospective randomized control trials on COPD 
patients and measured in the respective placebo arms with a 
follow-up of at least 3 years.
Results
The most important data concerning the average rate of FEV1 
decline prospectively measured in large COPD cohorts are 
shown in Table 1.
Only one large study was found about COPD patients 
with FEV1 higher than 80% of the predicted value (GOLD 
stage I). A total of 430 COPD patients recruited in the first 
stage of the Swiss Study on Air Pollution and Lung Diseases 
in Adults exhibited an average annual decline in FEV1 of 
about 40 mL/year over 11 years.4 Within this cohort, the sub-
group of asymptomatic patients had a slightly slower decline 
than those with chronic cough and phlegm.4 A much smaller 
cohort of GOLD stage I and II COPD patients was followed 
for 3 years in the Copenhagen City Heart Study,5 and this 
cohort showed a similar annual reduction in FEV1. Further 
studies are urgently needed to establish firmly how FEV1 
declines in GOLD stage I COPD patients. Data collected 
on COPD patients recruited in GOLD stage II (with FEV1 
between 79% and 50% of the predicted value) by Anthonisen 
et al (for the Lung Health Study [LHS]),6 Pauwels et al,7 
Anthonisen et al (for the LHS-3),8 the LHS Research Group,9 
and Jenkins et al10 are consistent, reporting a mean annual 
FEV1 decline of 56, 69, 53, 47, and 60 mL/year, respectively. 
However, it should be noted that in the post hoc analysis from 
the TORCH (TOwards a Revolution in COPD Health) study 
the placebo group did not faithfully represent the whole of 
GOLD stage II, because the inclusion criteria required a 
pre-bronchodilator FEV1 value of less than 60% of the pre-
dicted value.10 Accordingly, the COPD patients included in 
this placebo group had a baseline pre-bronchodilator FEV1 
between 60% and 50% of the predicted value. Recently 
published data in the Groningen Leiden Universities Cor-
ticosteroids in   Obstructive Lung Disease (GLUCOLD) 
study showed a decline in the placebo group greater than 
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Figure 1 Modified version of Fletcher and Peto’s1 graph showing the decline in the forced expiratory volume in the first second (FEV1).
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that found in previous studies, in average   amounting to 
79 mL/year.11 A secondary analysis of the Understanding 
Potential Long-term Impacts on Function with Tiotropium 
(UPLIFT) study evaluated the effects of long-term treat-
ment with tiotropium in GOLD stage II COPD patients.12 
Pre-bronchodilator FEV1 declined by a mean of 49 mL/year 
in the control group. However, this group was not a true 
placebo group, because all respiratory medications, except 
other inhaled anticholinergic drugs, were allowed during 
the trial and about 65% of these patients in the control arm 
were taking two active drugs. Because of this, the lower 
mean FEV1 decline in the UPLIFT control group cannot 
be considered as truly representative of GOLD stage II 
COPD. Therefore, it is reasonable to estimate that the mean 
post-bronchodilator FEV1 decline of GOLD stage II COPD 
patients amounts to 61 ± 12 mL/year, with a little bias toward 
the lowest initial FEV1 values in this stage. Lung function 
decline of COPD patients recruited in GOLD stage III is 
much better defined. In fact, Jenkins et al10 and Burge et al13 
had very homogeneous data with a mean FEV1 decline from 
56 to 59 mL/year. Interestingly, the FEV1 decline reported by 
Anzueto et al14 in a 1-year follow-up study performed in the 
same stage of COPD severity amounted in the placebo arm 
to 58 mL/year. The average FEV1 decline found by Decramer 
et al12 in GOLD stage III in the control arm of the UPLIFT 
study, amounting to 38 mL/year, is likely underestimated for 
the same reason mentioned above. A few data available 
about COPD patients recruited with FEV1 less than 30% of 
the predicted value have shown a much slower mean FEV1 
decline at GOLD stage IV than at other stages.10,12
Dawkins et al15 published interesting data about lung 
function decline in patients with alpha-1-antitrypsin 
deficiency-related emphysema stratified according to the 
GOLD guidelines (Table 2). In emphysematous COPD 
patients with the PiZ phenotype, the mean annual FEV1 
decline was higher in moderate disease, corresponding to 
GOLD stage II, and was greater than in the general COPD 
population. These data suggest that COPD patients suffering 
from panlobular emphysema have the highest rate of FEV1 
decline occurring in the early phase of the disease. This has   
Table 1 Rate of annual decline in the forced expiratory volume in the first second (FEV1) recorded in Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage I–IV chronic obstructive pulmonary disease patients randomized in the control arm during 
longitudinal studies with a follow-up period of at least 3 years
Reference Study GOLD stage Patients (n) Age range (yr) Follow-up period (yr) Mean FEV1 decline 
 (mL/yr)*
Bridevaux et al4 SAPALDIA 1 I 430 18–60 11 40 ± 37†
vestbo et al5 CCHS I–II 145 59 ± 10§ 3 42††
Anthonisen et al6 LHS II 1964 35–60 5 56††
Pauwels et al7 EUROSCOP II 643 30–65 3 69††
Anthonisen et al8 LHS-3 II 1357 30–60 11 53††
LHS Research Group9 LHS-2 II 557 40–69 3 47††
Jenkins et al10 TORCH II 535 40–80 3 60††
Lapperre et al11 GLUCOLD II 24 45–75 3 79††
Decramer et al12 UPLIFT II 1355 64 ± 9§ 4 49††
Burge et al13 ISOLDE III 375 40–75 3 59††
Jenkins et al10 TORCH III 775 40–80 3 56††
Decramer et al12 UPLIFT III 1331 65 ± 8§ 4 38††
Jenkins et al10 TORCH Iv 214 40–80 3 34††
Decramer et al12 UPLIFT Iv 271 63 ± 8§ 4 23††
Notes: §Mean age plus or minus the standard deviation; *standard deviation is shown when available; †pre-bronchodilator FEv1; ††post-bronchodilator FEv1.
Abbreviations: CCHS, Copenhagen City Heart Study; EUROSCOP, European Respiratory Society Study on Chronic Obstructive Pulmonary Disease; GLUCOLD, 
Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease study; ISOLDE, Inhaled Steroids in Obstructive Lung DiseasE study; LHS, Lung Health Study; 
LHS-2, Lung Health Study 2; LHS-3, Lung Health Study 3; SAPALDIA 1, first stage of the Swiss Study on Air Pollution and Lung Diseases in Adults; TORCH, TOwards a 
Revolution in COPD Health study; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium study; yr, year.
Table 2 Rate of annual decline of the forced expiratory volume in 
the first second (FEV1) in Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) stage I–IV chronic obstructive pulmonary 
disease  patients  with  alpha-1-antitrypsin  deficiency-related 
emphysema measured during a longitudinal study with a 3-year 
follow-up period15
GOLD  
stage
Patients  
(n)
Age range  
(yr)§
Mean FEV1*  
decline (mL/yr)§
I 18 49 ± 9 32 ± 19
II 26 51 ± 9 90 ± 19
III 38 53 ± 11 52 ± 8
Iv 19 49 ± 9   8 ± 9
Notes: §Data are presented as mean plus or minus the standard error of the mean; 
*pre-bronchodilator FEv1.
Abbreviation: yr, year.
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also been reported by Vestbo et al16 in a recently published 
paper on the change in FEV1 over time in the large COPD 
population enrolled in the Evaluation of COPD Longitudi-
nally to Identify Predictive Surrogate Endpoints (ECLIPSE) 
observational study. In this study patients with computerized 
tomography scan evidence of emphysema exhibited the larg-
est rate of FEV1 decline over a 3-year follow-up period.
Discussion
According to the evidence produced, it is clear that the loss 
of lung function, assessed as expiratory airflow reduction, 
is more accelerated and therefore more relevant in the 
early stages of COPD than in the late stages, with some 
reservation regarding GOLD stage I where consistent 
information is still lacking. Therefore, a different trend of 
the FEV1 decline in COPD can be envisaged (Figure 2), 
showing an opposite view to that of Fletcher and Peto’s 
diagram (  Figure 1). This is likely because COPD patients 
in the early stages have more to lose than those in the most 
advanced stage. In addition, some of the FEV1 loss can be 
partly buffered by the increase in total lung capacity in 
GOLD stage IV COPD patients.
Based on these findings, it seems that any attempt to 
positively interfere with the natural history of COPD by using 
different therapeutic options should logically be focused on 
COPD patients in at least GOLD stage II. This is suggested 
by the subgroup analysis of the treatment group in the GOLD 
stage II COPD patients of the UPLIFT study.12 Of course, 
this approach should be tested and proved by adequate 
  randomized clinical trials.17
It must be acknowledged that most of the recent large 
COPD trials studied had a 3- to 4-year follow-up period, 
which is much shorter than the follow-up period in Fletcher 
and Peto’s1 analysis; this could be a limitation in the accuracy 
of the FEV1 decline.
Furthermore, in many of these studies the percentage of 
dropouts was higher in the placebo arm, meaning that the 
average rate of FEV1 decline of healthier COPD patients 
is known rather than that of the true COPD population. 
As a consequence, the natural rate of FEV1 decline could 
be underestimated by the existing data. It is reasonable 
that this could be accentuated in the sicker COPD patients 
recruited in GOLD stage IV . However, the withdrawal from 
these studies is essentially because of symptoms and/or 
  exacerbations. Since FEV1 is poorly related to symptoms18 
and even to exacerbations,19 it is plausible that this reasoning 
may similarly be applied to each COPD stage, leaving the 
message of a greater loss of function in the early phase of 
the disorder still valid.
Finally, it should be recognized that the natural history of 
lung function, not only in healthy never smokers and smokers 
but also in COPD patients, has been essentially assessed in 
terms of expiratory airflow reduction, looking at the FEV1 
annual change as the primary measure to track the progressive 
decline of lung function. This could be a limitation, especially 
in very sick patients.
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Figure 2 Range of average rate of decline in the forced expiratory volume in the first second (FEV1) of chronic obstructive pulmonary disease patients according to initial 
severity of airflow reduction.
Notes: The dashed segment of the line highlights any stage or part of it where consistent information is still lacking; control data from the UPLIFT (understanding Potential 
Long-term Impacts on Function with Tiotropium) study were not considered in the analysis.
Abbreviation: yr, year.
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Conclusion
In summary, the authors have shown that information 
provided in recent years about the rate of FEV1 decline in 
COPD patients strongly supports the concept that the faster 
progression of functional impairment in COPD occurs 
early and it particularly occurs in GOLD stage II. This is 
in contrast with Fletcher and Peto’s1 analysis. In the present 
authors’ view it seems more logical to make efforts for an 
early (spirometric) detection of COPD, based on risk factors 
rather than symptoms, and to plan randomized clinical trials 
to show the efficacy of an early strategy of intervention on 
the natural history of such a disorder.
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